Identification of altered protein expression in major depressive disorder and bipolar disorder patients using liquid chromatography–tandem mass spectrometry

Hyeyoung Kim, Sang Jin Rhee, Hyunju Lee, Dohyun Han, Tae Young Lee, Minah Kim, Eun Young Kim, Jun Soo Kwon, Hyunsuk Shin, Hyeyoon Kim, Yong Min Ahn, Kyooseob Ha

Research output: Contribution to journalArticlepeer-review

Abstract

Emerging high-throughput proteomic technologies have recently been considered as a powerful means of identifying substrates involved in mood disorders. We performed proteomic profiling using liquid chromatography–tandem mass spectrometry to identify dysregulated proteins in plasma samples of 42 and 45 patients with major depressive disorder (MDD) and bipolar disorder (BD), respectively, in comparison to 51 healthy controls (HCs). Fourteen and six proteins in MDD and BD patients, respectively, were differentially expressed compared to HCs, among which coagulation factor XIII A chain (F13A1), platelet basic protein (PPBP), platelet facor 4 (PF4), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and thymosin beta-4 (TMSB4X) were altered in both disorders. For proteins dysregulated in both, except F13A1, higher fold changes were observed in MDD than in BD patients. These findings may help identify candidate biomarkers of mood disorders and elucidate their underlying pathophysiology and biochemical abnormalities.

Original languageEnglish
Article number113850
JournalPsychiatry Research
Volume299
DOIs
StatePublished - May 2021

Keywords

  • Biomarkers
  • Bipolar disorder
  • Major depressive disorder

Fingerprint Dive into the research topics of 'Identification of altered protein expression in major depressive disorder and bipolar disorder patients using liquid chromatography–tandem mass spectrometry'. Together they form a unique fingerprint.

Cite this